Looking ahead
The future of ADCs in the biopharmaceutical market will ultimately depend on their clinical success. Companies and researchers
are seeking to meet that challenge by optimizing the selection of all the components in the ADC—the antibody, linker, and
cytotoxin—and successfully combining manufacturing techniques for both high- potency APIs and biologics. ADCs are sometimes
described as armed antibodies, and their cytotoxic components as warheads. Whether ADCs will prove to be an effective weapon
against cancer or other diseases has yet to be seen as more are tested in the clinic.
References
1. FDA, "Label for Adcetris, BLA 125338," FDA Approved Drug Products: Drugs@FDA, accessed Dec. 20, 2011.
2. V.S. Goldmacher and Y.V. Kovtun, Ther. Deliv.
2 (3), 397–416 (2011).
3. F. Dosio, P. Brusa and L. Cattel, Toxins
3, 848–883 (2011).
4. H.A. Burris, Expert Opin. Biol. Ther.
11 (6), 807–819 (2011).
5. A. Beck et al., Discov. Med.
10 (53), 329–359 (2010).
6. S.V. Govindan and DM Goldenberg, Scientific World Journal
10, 2070–2089 (2010).
7. Junutula et al., Nat. Biotechnol.
26 (8), 925-932 (2008).
8. Junutula et al., Clin. Canc. Res.
16, 4769–4778 (2010).
9. A. Ritter Pharm. Tech.
35 (6), 36–39 (2011).
10. Zawada et al., Biotech. Bioeng.
108 (7), 1570–1578 (2011).
|
